NCT07179640View on ClinicalTrials.gov

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Hypophosphatasia (HPP)
Interventions
DRUG

ALE1

Specified dose on specified days

DRUG

Placebo

Specified dose on specified days

Trial Locations (1)

1010

New Zealand Clinical Research, Grafton

Sponsors
All Listed Sponsors
lead

Alesta Therapeutics

INDUSTRY

NCT07179640 - A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1 | Biotech Hunter | Biotech Hunter